Recall
FDAHealthOctober 9, 2025

Breckenridge Pharmaceutical, Inc. — Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceut

⚠️ CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
October 9, 2025

U.S. Nationwide

What's affected?

Product
Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain; Dist. by: Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ 07922.
Lot code
240721C

Additional details

90-count- Lot # 240721C; Exp. 02/28/2027 1000-count- Lot #230286C; Exp.02/28/2026

What should I do?

Recommended action

Class II recall. Voluntary: Firm initiated Quantity affected: 172,263 bottles.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.